Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Artrya Limited ( (AU:AYA) ) is now available.
Artrya Limited announced that its Co-Founder and CEO, John Konstantopoulos, will present at the 19th Annual Bioshares Investor Conference in Hobart. This presentation highlights Artrya’s commitment to advancing cardiac care through innovative technology, potentially enhancing its industry positioning and offering insights into its strategic direction for stakeholders.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$2.21 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions for the detection and management of coronary artery disease. Their primary product, the Salix® AI-powered cloud platform, analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in more accurate and efficient patient diagnoses. The company is actively engaged in regulatory and commercial activities across key international markets.
Average Trading Volume: 230,361
Technical Sentiment Signal: Buy
See more data about AYA stock on TipRanks’ Stock Analysis page.